Virax Biolabs Group Limited
VRAX · NASDAQ
9/30/2025 | 3/31/2025 | 9/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Market Cap | $2,896 | $4,967 | $6,008 | $1,641 |
| - Cash | $3,345 | $4,229 | $7,286 | $3,589 |
| + Debt | $538 | $377 | $603 | $224 |
| Enterprise Value | $89 | $1,115 | -$674 | -$1,724 |
| Revenue | $2 | $1 | $5 | $80 |
| % Growth | 16.7% | -72.2% | -93.8% | – |
| Gross Profit | -$215 | -$47 | -$6 | $40 |
| % Margin | -13,396.4% | -3,381.2% | -130.7% | 50.1% |
| EBITDA | -$2,369 | -$3,139 | -$2,767 | -$3,723 |
| % Margin | -147,336.7% | -227,823.3% | -55,861.2% | -4,658.2% |
| Net Income | -$2,339 | -$3,305 | -$2,756 | -$3,824 |
| % Margin | -145,446% | -239,827.3% | -55,651.7% | -4,784.7% |
| EPS Diluted | -0.49 | -0.76 | -0.89 | -1.71 |
| % Growth | 35.5% | 14.6% | 48% | – |
| Operating Cash Flow | -$2,923 | -$2,645 | -$1,919 | -$2,789 |
| Capital Expenditures | -$142 | -$356 | -$248 | -$460 |
| Free Cash Flow | -$3,065 | -$3,001 | -$2,167 | -$3,249 |